Cellectis S.A. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Cellectis S.A. is a clinical-stage biotechnology company whose core business is the development of allogeneic CAR-T cell therapies for cancer. The preclinical and clinical development of these genetically engineered cell therapies relies on animal testing. The company's public disclosures explicitly note that its product candidates are evaluated in animal studies, and that success in these models is a necessary but not guaranteed step toward human trials. This places animal experimentation at the center of its research and development pipeline.
The specific technology underpinning Cellectis's programs—TALEN gene-editing—is the subject of a September 2025 patent infringement complaint by Factor Bioscience. The lawsuit alleges that Cellectis's use of TALENs in its CAR-T and hematopoietic stem cell gene-editing programs infringes foundational patents. These disputed methods are directly applied to create the company's therapeutic candidates, which are subsequently tested in animal models.
Cellectis S.A. is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for cancer treatment. The company’s product development pipeline, as detailed in its annual SEC Form 20-F filings, is built on a foundation of preclinical animal testing. These filings consistently disclose that advancement of its therapeutic candidates into human clinical trials is contingent on “results of product development, laboratory and animal studies” and that “testing in animal studies” is a standard part of its research process. The company explicitly notes that results from these animal studies may not be sufficiently compelling to warrant further development.
As a pharmaceutical developer, Cellectis operates within a regulatory framework that currently mandates animal testing to evaluate the safety and efficacy of novel cell therapies before they can be tested in humans. The company’s disclosures confirm that animal testing is not an ancillary activity but an integral, funded component of its core business model for bringing new drugs to market.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.